Top technology trends for ablation devices Industry

Ablation therapies are emerging as an innovative way to treat chronic diseases like cancer and cardiovascular diseases. Manufacturers are developing ablation devices based on technologies like radio frequency, robotic-assisted surgeries, electrical, ultrasound and laser, which can destroy targeted or diseased tissues. Ablation devices have become a widely used and critical treatment method for cancer, irregular heartbeats, nerve pain and chronic bronchitis.

The potential of ablation devices is clear, and BCC Research expects the market to continue its growth curve. Estimated at $6.5 billion in 2022, BCC Research expects the market to reach $11.3 billion by 2027, growing at a rate of 11.8% from 2022 through 2027.

With growth on the horizon, technology innovation for ablation devices is rife, and competition is increasing. If one manufacturer develops radio frequency devices to treat arterial walls, another will develop a device that uses electrical energy to treat the same disease. This gives physicians better options for treating their patients because good quality devices with various technological applications are available in the market. Initially, manufacturers relied on thermal technologies such as radiation, light and microwave. The increased competition has also led to innovations as manufacturers invest more in research and development, which has also conducted some new non-thermal technologies, such as cryoablation and hydromechanical.

Changing demographics worldwide is another factor that has led to the evolution of the ablation devices market. The US has a population of nearly 78 million people who were born between 1946 and 1964. This baby boomer population makes up one-third of the country’s population. The global scenario is almost identical to that of the US. The reason for this baby boomer population was a drastic improvement in the fertility rate in the US, Europe and some other countries such as Australia and New Zealand. According to the US Census Bureau, by 2030, all boomers will be aged at least 65. Minimally invasive ablation therapies are better treatment options for the fragile and aging bodies of the baby boomer population. Manufacturers have kept this factor in mind and are developing ablation therapies for this aging population.

Technological advancement in ablation devices leads to cost-effective, innovative products that offer better treatment facilities for physicians and patients. The ablation devices market’s many innovations, such as radio frequency in thermal technologies and cryoablation in nonthermal technologies, are driving forces for the market, and the trend is expected to continue.

Technological advancements in radio frequency ablation (RFA) clinical experiments are initially carried out on animals, and upon successful implementation, they are used on human beings.

Ablation Devices: Technologies and Global Markets

Forward-looking industries have begun exploring the advantages of ablation devices, leading to a steady market. Growth opportunities are emerging, and BCC Research’s latest report helps players identify opportunities for ablation devices across various product categories and geographical segments.

Download Your Complimentary Report

Radiofrequency Ablation (RFA)

Radiofrequency ablation (RFA) uses heat to destroy tissue. It is used to treat chronic pain caused by conditions including arthritis of the spine and join pain, cancer pain, facial pain caused by trigeminal neuralgia, peripheral nerve pain, tumors to kill cells, and the treatment of primary and secondary liver cancer. The challenge with liver cancer is that it cannot be diagnosed until the patient presents severe symptoms; however, by then, the tumor has usually grown too big to treat with normal surgery. RFA allows treatment of such late-diagnosed liver cancer. This technological innovation of radio frequency can treat inoperable tumors. In recent years, RF ablation balloons have also been developed.

Pulsed Field Ablation (PFA)

Pulsed-field ablation (PFA) has recently emerged as an emerging technology for ablation. It is a new adaptation of low-energy DC catheter ablation. It uses large electrodes to reduce current density. PFA is a tool for non-thermal ablation. Based on recent studies, the myocardium is more susceptible to PFA’s effects than other tissues, particularly the esophagus and nerves. Therefore, PFA is less likely to produce collateral damage than RF ablation during pulmonary vein isolation procedures.

Robotic Tissue Ablation

Robotic tissue ablation is a clinical procedure the employs robots to remove or destroy the diseased tissue or tumor from the body. This system has a robotic surgical arm that helps in removing diseased tissue. This technique prevents conventional manual ablation methods. Its superiority, driven by increased precision, stability and efficacy, assures safety from potential human errors. Robotic tissue ablation procedures provide exceptional accuracy, quick healing and excellent outcomes, making them a significant innovation in medicine. In the near future, the surgery market is expected to be driven by robotic tissue ablation, which will surpass traditional ablation surgery methods.

Microwave Endometrial Ablation

Endometrial ablation is another segment where innovations are likely to change how gynecological ailments can be treated. New devices will be launched, and strategic partnerships will be formed for innovations in endometrial ablation. Microwave endometrial ablation is a new treatment for dysfunctional uterine bleeding that involves applying microwave energy to the endometrium. Other innovations emerging in the ablation devices market include cardiac ablation, electrophysiology mapping and cancer ablation devices.

Nanomaterials in Cryoablation

Nanomaterials in cryoablation are a new opportunity. Despite its ease of use and efficiency, cryoablation still faces problems such as inadequate ice formation, the possibility of the ice ball overextending into healthy tissues and low tumor cell death. Due to these factors, recurrence can occur in tumors treated with cryoablation. Image-guided cryoablation is needed for the precision targeting of tumors. Nanomaterials can act as both imaging contrast agents and vehicles of chemotherapeutic drugs. Nanoparticles can increase and direct ice growth, protect healthy tissues from cryoinjury, damage cells via modulating their membranes, locally release drugs and enhance imaging.

Learn more about the market for ablation devices

Alternatively, consider becoming a member of the BCC Research library, and gain access to the full catalog of reports within the healthcare category. Enquire today to find out more.